Neoadjuvant Chemotherapy for the Treatment of Resectable Locally Advanced Colon Cancer

Overview

A randomized controlled clinical trial to compare the short and long outcomes of Neoadjuvant chemotherapy with postoperative chemotherapy in patients with resectable locally advanced colon cancer

Full Title of Study: “A Randomized Controlled Clinical Trial to Investigate the Effect of Neoadjuvant Chemotherapy for the Treatment of Resectable Locally Advanced Colon Cancer”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2021

Detailed Description

For resectable locally advanced colon cancer, the preferred treatment is colectomy with en bloc removal of the regional lymph nodes followed by chemotherapy of about 6 months. However, surgery may postpone the administration of chemotherapy due to postoperative complications such as anastomosis leakage, abdominal infection, thus leads to a poor survival. Some scholars suggested that for patients with locally advanced colon cancer, chemotherapy given before surgery might shrink or downstage tumor, facilitate surgery and promote a better oncological outcome. Whether adjuvant chemotherapy benefits these patients with better outcome still remains controversial. In this study, eligible patients will be randomly allocated to receive either adjuvant chemotherapy or not. For patients receiving adjuvant chemotherapy, surgery will be performed 3-4 weeks later. Preoperative and postoperative chemotherapy will be given for a total of about 6 months. For patients receiving no preoperative chemotherapy, chemotherapy will be given for about 6 months postoperatively. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy. Patients will be followed up every 3 months for 2 year, every 6 months for 3 years postoperatively.

Interventions

  • Drug: Postoperative chemotherapy
    • Locally advanced colon cancer patients will receive surgery first, followed by 6 months of chemotherapy. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy.
  • Drug: Neoadjuvant chemotherapy
    • Neoadjuvant chemotherapy will be given to locally advanced colon cancer patients for 3-4 cycles. Surgery will be performed between 3 to 4 weeks subsequent to the last cycle of chemotherapy. After surgery, additional chemotherapy will be given. Preoperative and postoperative chemotherapy will be given for a total of 6 months. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy.

Arms, Groups and Cohorts

  • Active Comparator: Postoperative chemotherapy
    • Patients receive 6 months of chemotherapy after surgery.
  • Experimental: Neoadjuvant chemotherapy
    • Patients receive 3-4 cycles of chemotherapy before surgery. Preoperative and postoperative chemotherapy will be given for a total of 6 months.

Clinical Trial Outcome Measures

Primary Measures

  • disease-free survival
    • Time Frame: 3 years

Secondary Measures

  • overall survival
    • Time Frame: 3 years
  • recurrence-free survival
    • Time Frame: 3 years
  • local recurrence rate
    • Time Frame: 3 years
  • length of postoperative hospital stay
    • Time Frame: 30 days
    • Length of postoperative hospital stay is defined as a duration between surgery and first discharge. An expected average is 10 days.
  • early complication rate
    • Time Frame: 30 days
    • Early complication is defined as a complication that occurred between the finish of the surgery and postoperative day 30. Complications includes anastomotic leakage, anastomotic bleeding, chyle leakage, wound infection, pulmonary embolism, myocardial infarction et al.The Clavien-Dindo Classification of Surgical Complications will be applied to access the degree of severity of postoperative complications.
  • operative time
    • Time Frame: 1 day
  • number of lymph nodes retrieved
    • Time Frame: 1 day

Participating in This Clinical Trial

Inclusion Criteria

  • Patients suitable for curative surgery between 18 to 80 years old; – American Society of Anesthesiologists(ASA) grade I-III; – Pathological diagnosis of adenocarcinoma; – Tumor located between the cecum and sigmoid colon; – Enhanced CT scan of chest, abdominal and pelvic cavity: preoperative assessment of tumor stage is T3-T4 N0 or T any N+ (according to the National Comprehensive Cancer Network(NCCN) clinical practice guidelines in oncology: colon cancer version 2.2015);there is no distant metastasis; – Informed consent; – No preoperative chemoradiotherapy; – No history of familial adenomatous polyposis, ulcerative colitis or Crohn's disease. Exclusion Criteria:

  • Pregnant patient; – History of psychiatric disease; – Use of systemic steroids; – Simultaneous multiple primary colorectal cancer; – Preoperative imaging examination results show: 1. distant metastasis; 2. unable to perform R0 resection; – Postoperative pathology of T1-T2 N0; – History of any other malignant tumor in recent 5 years; – Patients need emergency operation: mechanic ileus, perforation.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • The First Affiliated Hospital with Nanjing Medical University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Fumin Zhang, Professor, Study Director, Ethics Committee of the First Affiliated Hospital, Nanjing Medical University, Jiangsu Province Hospital
  • Overall Contact(s)
    • Yueming Sun, PhD, 02568136026, jssym@vip.sina.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.